Login / Signup

An ErbB2/c-Src axis links bioenergetics with PRC2 translation to drive epigenetic reprogramming and mammary tumorigenesis.

Harvey W SmithAlison HirukawaVirginie Sanguin-GendreauIpshita NandiCatherine R DufourDongmei ZuoKristofferson TandocMatthew LeibovitchSalendra SinghJonathan P RennhackMatthew SwiatnickiCynthia LavoieVasilios PapavasiliouCarolin TempsNeil O CarragherAsier Unciti-BrocetaPaul SavageMark BasikVincent van HoefOla LarssonCaroline L CooperAna Cristina Vargas CalderonJane BeithEwan MillarChristina SelingerVincent GiguèreMorag ParkLyndsay N HarrisVinay VaradanEran R AndrechekSandra A O'TooleIvan TopisirovicWilliam J Muller
Published in: Nature communications (2019)
Dysregulation of histone modifications promotes carcinogenesis by altering transcription. Breast cancers frequently overexpress the histone methyltransferase EZH2, the catalytic subunit of Polycomb Repressor Complex 2 (PRC2). However, the role of EZH2 in this setting is unclear due to the context-dependent functions of PRC2 and the heterogeneity of breast cancer. Moreover, the mechanisms underlying PRC2 overexpression in cancer are obscure. Here, using multiple models of breast cancer driven by the oncogene ErbB2, we show that the tyrosine kinase c-Src links energy sufficiency with PRC2 overexpression via control of mRNA translation. By stimulating mitochondrial ATP production, c-Src suppresses energy stress, permitting sustained activation of the mammalian/mechanistic target of rapamycin complex 1 (mTORC1), which increases the translation of mRNAs encoding the PRC2 subunits Ezh2 and Suz12. We show that Ezh2 overexpression and activity are pivotal in ErbB2-mediated mammary tumourigenesis. These results reveal the hitherto unknown c-Src/mTORC1/PRC2 axis, which is essential for ErbB2-driven carcinogenesis.
Keyphrases